Key clinical point: Melflufen plus dexamethasone is active in patients with relapsed/refractory multiple myeloma, whether or not they have extramedullary disease.
Major finding: The overall response rate was 23% in patients with extramedullary disease and 27% in those without.
Study details: A phase 2 trial of 130 patients, 44 with extramedullary disease and 86 without it.
Disclosures: The trial is sponsored by Oncopeptides. Dr. Richardson reported an advisory role and research funding from Oncopeptides.
Richardson PG et al. IMW 2019, Abstract OAB-086.